Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study (Q83801480)
Jump to navigation
Jump to search
scientific article published on 02 April 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study |
scientific article published on 02 April 2012 |
Statements
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study (English)
Olav Dahl
Thoralf Christoffersen
Eva Hofsli
Bengt Glimelius
Kjell Magne Tveit
Tormod Guren
Halfdan Sorbye
Seppo Pyrhonen
Fridbjorn Sigurdsson
Elin Kure
Tone Ikdahl
Eva Skovlund
Flemming Hansen
Elke Birkemeyer
Anders Johnsson
Hans Starkhammar
Mette Karen Yilmaz
Nina Keldsen
Anne Berit Erdal